Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 278

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 278
---
     | $     | 354.15 |     | $     | 559.00 |     | $     | 965.14 |
| EBITDA          |     |       |  (7.82 | ) |     |       | (15.00 | ) |     |       |   3.98 |   |     |       |  51.21 |   |     |       |  73.68 |     |       | 111.17 |     |       | 439.92 |
| Net cash flow   |     | $     | (14.26 | ) |     | $     | (12.75 | ) |     | $     | (17.33 | ) |     | $     |  (7.11 | ) |     | $     |   1.78 |     | $     |   15.5 |     | $     | 188.95 |

Projected revenue was based on numerous assumptions, including: •Development of the revenue estimates for Lumee Oxygen and Lumee Glucose relied on calculations of the total addressable market available to potential penetration by both products. In the case of Lumee Glucose, revenue includes both sales of Lumee Glucose in its personal use and professional -useapplications. Profusa calculated the total addressable market by defining relevant active market segments in both the United States and European Union for both Lumee Oxygen and Lumee Glucose. The projections assumed that revenue build for Lumee Oxygen would commence in Q4 of 2022, and Q2 of 2024 for Lumee Glucose. •Furthermore, Lumee Glucose revenue numbers are cross -referencedand viability -checkedwith the patient launch numbers for existing competitor Abbott, manufacturers of the Freestyle Libre CGM system. Abbott was used as a reference point since it is a recent entrant to the market and Abbott’s launch numbers are indicated in existing Wall Street sell -sideanalyst coverage. In the United States, Abbott showed more than 100,000 patients for end of year 2018, after personal -useCGM launch end of 2017. Abbott was used as a reference point and not as a target for the patient numbers Profusa expects to achieve. Abbott was able to attain rapid market share due to, among other factors, its competitive lowest -in-the-marketEU and US pricing vs. Dexcom and Medtronic. As opposed to assuming Profusa’s relative pricing advantage to existing players